tbuckley/cabot-search huggingface dataset:
A State-of-the-Art Review Highlighting Medical Overuse in Dermatology, 2017-2018
Authors: Ashley B. Pournamdari, Elizabeth Tkachenko, John Barbieri, Adewole S. Adamson, Arash Mostaghimi
Journal: JAMA Dermatology (2019)

Emerging efforts to recognize and combat medical overuse are important solutions to mitigate patient morbidity from unnecessary health care interventions.To identify and highlight important original investigations on medical overuse in dermatology from 2017 to 2018.The PubMed and Embase databases coupled with articles published in 8 major dermatology and medical journals from January 1, 2017, to December 31, 2018, were searched to identify articles related to medical overuse in dermatology.Of 1941 candidate articles identified through the database search and 41 through the manual journal review, 38 were deemed relevant to medical overuse in dermatology by 2 independent reviewers. Twenty-eight of these articles were determined to be high priority based on scoring for quality of methods, magnitude of clinical effect, and number of patients potentially affected. After expert reviewer scoring, 10 articles were selected for analysis based on highest scores and greatest clinical significance. Selected articles covered topics such as dermatology consultation for cellulitis, management of dysplastic nevi, prognostic utility of sentinel lymph node biopsy, laboratory monitoring for terbinafine and isotretinoin, and safe medication prescribing. For cellulitis management, dermatology consultation is important for reducing misdiagnosis, unnecessary hospitalization, and inappropriate use of antibiotics. Findings related to common dermatologic procedures revealed that clinical observation is safe for dysplastic nevi and that sentinel lymph node biopsy may not have prognostic utility over Breslow thickness. In monitoring for terbinafine and isotretinoin, patient education on clinical symptoms is likely more effective than standard laboratory test result monitoring. Finally, dermatologists should reconsider the use of cyclosporine in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis and reevaluate the use of perioperative narcotics for patients.This review notes actionable, evidence-based practices to reduce medical overuse in dermatology. This work may help to facilitate management changes to emphasize high-value care in dermatology while promoting awareness and further evaluation of overuse in medicine.
P1.11-30 Very Rapid Growth of Small Pulmonary Nodules Predicts Benignity
Authors: J. Barnett, I. Pulzato, T. Burn, S. Zafar, J. Hine, E. Bartlett, P. Shah, A. Nicholson, C. Ridge, S. Padley, P. Molyneaux, S. Kemp, A. Devaraj
Journal: Journal of Thoracic Oncology (2019)
EP1.18-19 Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice
Authors: K. Furuhashi, O. Hataji, Y. Nakamura, Y. Suzuki, T. Sakaguchi, K. Ito, K. Fujiwara, Y. Nishii, O. Taguchi
Journal: Journal of Thoracic Oncology (2019)
Thiopurine-mediated impairment of hematopoietic stem and leukemia cells in Nudt15R138C knock-in mice
Authors: Goichi Tatsumi, Masahiro Kawahara, Takayuki Imai, Ai Nishishita-Asai, Atsushi Nishida, Osamu Inatomi, Akihiko Yokoyama, Yoichi Kakuta, Katsuyuki Kito, Akira Andoh
Journal: Leukemia (2019)
The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT).
Authors: Elias J. Anaissie, Monica L. Grazziutti, Dong Li, Marisa H. Miceli, Athanasios Fassas, Raymond Thertulien, Sabitha Rajan, Fariba Saghafifar, Guido J. Tricot, Bart Barlogie
Journal: Blood (2004)
EP1.04-19 First Experience with Atezolizumab in Slovakia
Authors: P. Kasan, P. Berzinec, M. Cerna, I. Andrasina, A. Cipkova, G. Chowaniecova, L. Denkova, R. Godal, H. Kuzmova, Z. Svihelova – Liskova, M. Martak, J. Mazal, J. Obertova, Z. Pribulova, M. Urda, M. Vesela
Journal: Journal of Thoracic Oncology (2019)
P2.16-07 How to Manage Toxicities of EGFR-TKI for Extreme Elderly Lung Cancer Patients: Supportive Care for Patients Aged 85 and Older
Authors: Y. Seki, T. Kazuyori, A. Sato, S. Fujimoto, M. Yamada, Y. Yamanaka, I. Fujisaki, K. Odashima, A. Seki, T. Ishikawa, K. Kuwano
Journal: Journal of Thoracic Oncology (2019)
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Authors: Wendy Mao, Ali Ghasemzadeh, Zachary T. Freeman, Aleksandar Obradovic, Matthew G. Chaimowitz, Thomas R. Nirschl, Emily McKiernan, Srinivasan Yegnasubramanian, Charles G. Drake
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Prostate cancer responds poorly to current immunotherapies. Epigenetic therapies such as BET Bromodomain inhibition can change the transcriptome of tumor cells, possibly making them more immunogenic and thus susceptible to immune targeting. <h3>Methods</h3> We characterized the effects of BET bromodomain inhibition using JQ1 on PD-L1 and HLA-ABC expression in two human prostate cell lines, DU145 and PC3. RNA-Seq was performed to assess changes on a genome-wide level. A cytotoxic T cell killing assay was performed in MC38-OVA cells treated with JQ1 to demonstrate increased immunogenicity. In vivo experiments in the Myc-Cap model were conducted to show the effects of JQ1 administration in concert with anti-CTLA-4 checkpoint blockade. <h3>Results</h3> Here, we show that targeting BET bromodomains using the small molecule inhibitor JQ1 decreased PD-L1 expression and mitigated tumor progression in prostate cancer models. Mechanistically, BET bromodomain inhibition increased MHC I expression and increased the immunogenicity of tumor cells. Transcriptional profiling showed that BET bromodomain inhibition regulates distinct networks of antigen processing and immune checkpoint molecules. In murine models, treatment with JQ1 was additive with anti-CTLA-4 immunotherapy, resulting in an increased CD8/Treg ratio. <h3>Conclusions</h3> BET Bromodomain inhibition can mediate changes in expression at a genome wide level in prostate cancer cells, resulting in an increased susceptibility to CD8 T cell targeting. These data suggest that combining BET bromodomain inhibition with immune checkpoint blockade may have clinical activity in prostate cancer patients.
EP1.11-18 Follow-up and Recurrence After Surgery in Patients with Non-Small-Cell Lung Cancer
Authors: F. Martelo, M. Felizardo, M.O. Fernandes, M. Pantarroto, M. Grafino, J. Eurico Reis, A. Catarino, A. Ribeiro, C. Loewenthal, R. Vieira, F. Mascarenhas
Journal: Journal of Thoracic Oncology (2019)
Novel Treatment of a Vaccinia Virus Infection from an Occupational Needlestick — San Diego, California, 2019
Authors: Erin R. Whitehouse, Agam K. Rao, Yon C. Yu, Patricia A. Yu, Margaret Griffin, Susan Gorman, Kristen A. Angel, Eric C. McDonald, Anna Liza Manlutac, Marie A. de Perio, Andrea M. McCollum, Whitni Davidson, Kimberly Wilkins, Eddy Ortega, Panayampalli S. Satheshkumar, Michael B. Townsend, Marcia Isakari, Brett W. Petersen
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Vaccinia virus (VACV) is an orthopoxvirus used in smallpox vaccines, as a vector for novel cancer treatments, and for experimental vaccine research (1). The Advisory Committee on Immunization Practices (ACIP) recommends smallpox vaccination for laboratory workers who handle replication-competent VACV (1). For bioterrorism preparedness, the U.S. government stockpiles tecovirimat, the first Food and Drug Administration-approved antiviral for treatment of smallpox (caused by variola virus and globally eradicated in 1980*,†) (2). Tecovirimat has activity against other orthopoxviruses and can be administered under a CDC investigational new drug protocol. CDC was notified about an unvaccinated laboratory worker with a needlestick exposure to VACV, who developed a lesion on her left index finger. CDC and partners performed laboratory confirmation, contacted the study sponsor to identify the VACV strain, and provided oversight for the first case of laboratory-acquired VACV treated with tecovirimat plus intravenous vaccinia immunoglobulin (VIGIV). This investigation highlights 1) the misconception among laboratory workers about the virulence of VACV strains; 2) the importance of providing laboratorians with pathogen information and postexposure procedures; and 3) that although tecovirimat can be used to treat VACV infections, its therapeutic benefit remains unclear.
Orotate phosphoribosyl transferase and XPA expressions as predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers
Authors: Y. Hasegawa, N. Hanai, A. Terada, T. Ozawa, M. Goto
Journal: Journal of Clinical Oncology (2009)

6084 Background: The main purpose of the present study was to find predictive biomarkers that can be routinely used for the response to chemotherapy in head and neck squamous cell carcinomas. From this standpoint, we have investigated the gene expression profile of individual tumors as available predictive biomarkers. Methods: Sixty-four tumor specimens from patients undergoing radical treatment for squamous cell carcinomas of the oro- and hypopharynx in stage II, III, or IV, were included in the present study. There were 30 primary tumors sites in the oropharynx and 34 in the hypopharynx, respectively. All patients were administered induction chemotherapy (FP) with a combination of 5-FU (800 (600) mg/m 2 d1–5 (6)) and cisplatin (80 mg/m 2 d6 (7)) before definitive therapy. This chemotherapy was used in order to select patients for organ preservation based on the response and decrease in late salvage surgery rate. Treatment was repeated every 3 to 4 weeks. Using biopsy specimens, we analyzed their gene expression profiles with the following 25 markers, which we thought were likely predictors of the response to anti-cancer agents: TS, DPD, OPRT, TP, COX2, MDR1, MRP1, VEGF, EGFR, HER2, PIK3CA, PTEN, p53, Rb1, Bcl2, BclX, BAX, GSTπ, ERCC1, XPA, E2F1, ENT1, Rev3, β-tubulin, and Survivin. These mRNA expressions were quantified by real-time reverse transcription polymerase chain reaction (real-time RT-PCR) assay. Clinical markers, such as T and N factor, gender and age were added, and logistic regression analysis and likelihood ratio test were conducted. Results: Univariately, response for chemotherapy was significantly correlated with T factor (p = 0.015), and the mRNA expression level of XPA (p = 0.018) and OPRT (p = 0.047). Meanwhile, using a multivariate logistic regression analysis with these factors (clinical markers, OPRT and XPA), T factor (p = 0.048) and the expression of XPA (p = 0.035) were demonstrated to be independent predictors for chemotherapy. Conclusions: XPA (Xeroderma Pigmentosum A) and OPRT (Orotate phosphoribosyl transferase) may be possible reliable predictive biomarkers for FP therapy, and might help the decision-making strategy for individual patients with head and neck cancers. No significant financial relationships to disclose.
P2.18-13 Endobronchial Brachytherapy: A Single Institutional Experience
Authors: P. Trias Sabrià, J. Mases Rosinés, M.R. López-Lisbona, N. Cubero De Frutos, M. Díez-Ferrer, S. Padrones Sanchez, S. Aso-González, D. Najjari Jamal, I. Visus Fernández De Manzano, A. Slocker Escarpa, J. Dorca Sargatal, C. Gutierrez Miguelez
Journal: Journal of Thoracic Oncology (2019)
Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study
Authors: Linghui Zhou, Yujiao Deng, Na Li, Yi Zheng, Tian Tian, Zhen Zhai, Si Yang, Qian Hao, Ying Wu, Dingli Song, Dai Zhang, Jun Lyu, Zhijun Dai
Journal: Journal of Hematology & Oncology (2019)

Abstract Background Hodgkin lymphoma (HL) is an uncommon B cell lymphoma. We assessed the global, regional, and national burden of HL from 1990 to 2017, by gender, age, and social-demographic index (SDI). Methods Data on HL, including incidence, mortality, and disability adjusted life-years (DALY), from 1990 to 2017 were obtained from the 2017 Global Burden of Disease study. Estimated annual percentage changes (EAPCs) were calculated to assess incidence rate, mortality, and DALY trends. Results HL incidences increased by 38.66%, from 72,937 in 1990 to 101,133 in 2017, while the age-standardized incidence rate (ASIR) was relatively stable. ASIR decreased in the low SDI regions (EAPC = − 2.58; 95% CI, from − 2.66 to − 2.49) and was stable in the other four SDI regions. Incidence showed a bimodal distribution with peak values in patients aged 20–39 years and patients aged 60 years or higher. The number of death cases and DALYs were stable. The age-standardized death rate decreased by 2.36% (95% CI, from − 2.43% to − 2.30%) per year. The annual age-standardized DALY rate decreased by 2.29% (95% CI, from − 2.36% to − 2.21%). The incidence and mortality in male subjects was higher than that in female subjects. The incidence in male and female subjects aged 15–30 years old was close, whereas the biggest difference existed in patients aged &lt; 10 years old and 45–75 years old between genders. Conclusion Globally, incidence of HL was stable, while mortality and DALY rate of HL had been decreasing from 1990 to 2017. Compared with lower and decreasing ASIR in the low SDI region, ASIR in the high SDI region was always high, indicating the need for HL treatment improvement and the establishment of more targeted and specific strategies in high SDI countries to reduce the incidence of HL.
MA09.03 Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
Authors: Y. Elamin, J. Robichaux, B. Carter, M. Altan, D. Gibbons, F. Fossella, G. Simon, V. Lam, G. Blumenschein, A. Tsao, J. Kurie, F. Mott, M. Negrao, L. Hu, J. He, M. Nilsson, B. Roeck, Z. Yang, V. Papadimitrakopoulou, J. Heymach
Journal: Journal of Thoracic Oncology (2019)
EP1.14-14 MUC1 Confers Chemotherapy Resistance of Tumor-Initiating Cells Through EGFR-IL-6 Axis
Authors: L. Huang, Y. Lv, W. Cang, Q. Li, X. Liao, H. Deng, G. Chen, L. Qiu
Journal: Journal of Thoracic Oncology (2019)
miR24-2 Promotes Malignant Progression of Human Liver Cancer Stem Cells by Enhancing Tyrosine Kinase Src Epigenetically
Authors: Liyan Wang, Xiaonan Li, Wei Zhang, Yuxin Yang, Qiuyu Meng, Chen Wang, Xiaoru Xin, Xiaoxue Jiang, Shuting Song, Yanan Lu, Hu Pu, Xin Gui, Tianming Li, Jie Xu, Jiao Li, Song Jia, Dongdong Lu
Journal: Molecular Therapy (2019)

MicroRNA24-2 (miR24-2) is associated with human tumorigenesis; however, its molecular mechanisms are poorly understood. Herein, our findings demonstrate that miR24-2 promotes the proliferation ability in vitro and the tumorigenic ability in vivo in human liver cancer stem cells (hLCSCs). Mechanically, the miR24-2 targets for 3' UTR (2,627-2,648) of protein arginine methyltransferase 7 (PRMT7) inhibit the translational ability of prmt7 gene. Moreover, miR24-2 inhibits the di-/tri-methylation of histone H4 arginine 3 by reducing PRMT7 and then promotes the expression of Nanog via long noncoding RNA HULC. Notably, miR24-2 inhibits histone deacetylase HDAC3 through miR675, which promotes the acetylation of histone H4 at lysine 16. Subsequently, miR24-2 enhances the interaction between LC3 and ATG4 dependent on PI3K and triggers cellular autophagy. Strikingly, miR24-2 inhibits the degradation of pyruvate kinase M1 via autophagosome-P62 in hLCSCs. Furthermore, miR24-2 enhances the activity of Src by promoting the binding of PKM1 to the Src promoter regions in hLCSCs. In particular, our results also indicate that src gene determines the oncogenic functions of miR24-2. These results provided a valuable theoretical basis for the discovery of liver cancer therapeutic targets and diagnosis markers based on miR24-2.
P2.06-06 Y-box Binding Protein-1, a Potential Target in Malignant Pleural Mesothelioma, Drives Growth Through Distinct Mechanisms
Authors: T. Johnson, K. Schelch, M. Williams, Y.Y. Cheng, M. Grusch, G. Reid, A. Burgess
Journal: Journal of Thoracic Oncology (2019)
Routine repeated echocardiographic monitoring of fetuses exposed to maternal anti-SSA antibodies: time to question the dogma
Authors: Nathalie Costedoat-Chalumeau, Nathalie Morel, Rebecca Fischer-Betz, Kateri Levesque, Alice Maltret, Munther Khamashta, Antonio Brucato
Journal: The Lancet Rheumatology (2019)
P2.01-65 Temporal Changes of Radiation-Induced Lung Injury Following Proton Therapy for Non-Small Cell Lung Cancer (NSCLC)
Authors: L. Roshkovan, A. Lozano, A. Hanlon, V. Jain, K. Cengel, C. Simone Li, A. Berman, S. Feigenberg, S. Katz
Journal: Journal of Thoracic Oncology (2019)
P2.01-40 Normalization of Carcinoembryonic Antigen Levels Is Associated with Survival Improvement in Patients with Advanced Non-Small Cell Lung Cancer
Authors: R. Sánchez-Reyes, E. Varela-Santoyo, A. Pereira-García, F. Barrón, A.F. Cardona, L. Cabrera-Miranda, E. Vergara, L. Corrales, C. Martin, O.G. Arrieta
Journal: Journal of Thoracic Oncology (2019)
MA13.06 Ph3 Study of Maintenance Therapy with S-1 vs BSC After Induction Therapy with Carboplatin + S-1 for Advanced Squamous Cell Lung Cancer (WJOG7512L)
Authors: K. Tanaka, S. Morita, M. Ando, T. Yokoyama, A. Nakamura, H. Yoshioka, T. Ishiguro, S. Miura, R. Toyozawa, T. Oguri, H. Daga, R. Ko, A. Bessho, M. Tachihara, Y. Iwamoto, K. Hirano, Y. Nakanishi, K. Nakagawa, N. Yamamoto, I. Okamoto
Journal: Journal of Thoracic Oncology (2019)
EP1.03-09 Epidemiological Study of TSC1 Mutations Among Non-Small Cell Lung Cancer Patients in China
Authors: Y. Fang, C. Xu, W. Wang, H. Pan, Q. Zhang, W. Zhuang, Y. Zhu, Z. Huang, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
Phase 1 Clinical Trial of KOS-953 + Bortezomib (BZ) in Relapsed Refractory Multiple Myeloma (MM).
Authors: Asher Alban Chanan-Khan, P. G. Richardson, M. Alsina, M. Carroll, S. Lonial, A. Krishnan, M. Albitar, Y. Zhou, C. Mitsiades, G. Cropp, A. L. Hannah, K. C. Anderson
Journal: Blood (2005)
AP-1 activity induced by co-stimulation is required for chromatin opening during T cell activation
Authors: Masashi Yukawa, Sajjeev Jagannathan, Sushmitha Vallabh, Andrey V. Kartashov, Xiaoting Chen, Matthew T. Weirauch, Artem Barski
Journal: The Journal of Experimental Medicine (2019)

Activation of T cells is dependent on the organized and timely opening and closing of chromatin. Herein, we identify AP-1 as the transcription factor that directs most of this remodeling. Chromatin accessibility profiling showed quick opening of closed chromatin in naive T cells within 5 h of activation. These newly opened regions were strongly enriched for the AP-1 motif, and indeed, ChIP-seq demonstrated AP-1 binding at >70% of them. Broad inhibition of AP-1 activity prevented chromatin opening at AP-1 sites and reduced the expression of nearby genes. Similarly, induction of anergy in the absence of co-stimulation during activation was associated with reduced induction of AP-1 and a failure of proper chromatin remodeling. The translational relevance of these findings was highlighted by the substantial overlap of AP-1-dependent elements with risk loci for multiple immune diseases, including multiple sclerosis, inflammatory bowel disease, and allergic disease. Our findings define AP-1 as the key link between T cell activation and chromatin remodeling.
P1.11-13 Mass Spectrometry Proteomics Analysis Discovers Biomarkers in Serum Months to Years Before Non-Small Cell Lung Cancer: The HUNT Study
Authors: O.T. Nguyen, M. Markaki, A. Sharma, C. Chatzipantsiou, V. Lagani, I. Tsamardinos, O. Røe
Journal: Journal of Thoracic Oncology (2019)
The macro-metastasis/organ parenchyma interface (MMPI) - A hitherto unnoticed area
Authors: R. Blazquez, D. Sparrer, C. Wendl, M. Evert, M.J. Riemenschneider, M.P. Krahn, N. Erez, M. Proescholdt, T. Pukrop
Journal: Seminars in Cancer Biology (2019)

The macro-metastasis/organ parenchyma interface (MMPI) was previously considered an inert anatomical border which sharply separates the affected organ parenchyma from the macro-metastatic tissue. Recently, infiltrative growth of macro-metastases from various primary tumors was described in the brain, liver and lung, with significant impact on survival. Strikingly, the MMPI patterns differed between entities, so that at least nine different patterns were described. The MMPI patterns could be further classified into three major groups: displacing, epithelial and diffuse infiltrating. Additionally, macro-metastases are a source of further tumor cell dissemination in the affected organ; and these intra-organ metastatic dissemination tracks starting from the MMPI also vary depending on the anatomical structures of the colonized organ and influence disease outcome. In spite of their relevance, MMPIs and organ-specific dissemination tracks are still largely overlooked by many clinicians, pathologists and/or researchers. In this review, we aim to address this important issue and enhance our current understanding of the different MMPI patterns and dissemination tracks in the brain, liver and lung.
Prevention of HIV Transmission and the HPTN 052 Study
Authors: Myron S. Cohen, Theresa Gamble, Marybeth McCauley
Journal: Annual Review of Medicine (2019)

The HIV Prevention Trials Network 052 study (HPTN 052) was a clinical trial designed to determine whether early treatment for HIV infection prevented transmission of the virus in couples where one partner was infected with HIV and the other was not, referred to as HIV serodiscordant or serodifferent couples. The study enrolled 1,763 couples at 13 sites in 9 countries in Asia, Africa, and the Americas. HPTN 052 demonstrated a minimum of 96% reduction of HIV in heterosexual couples ascribed to antiretroviral treatment; early treatment of HIV significantly reduced other infections in the HIV-infected subjects. This study, in conjunction with similar research, led to significant changes in international HIV treatment guidelines and the concept of treatment as prevention (TasP). This article provides the scientific background and history of how HPTN 052 came into being, the challenges it faced, and the ultimate impact it had on the fields of HIV treatment and prevention.
Cases in Precision Medicine: The Role of Tumor and Germline Genetic Testing in Breast Cancer Management
Authors: Jonah Tischler, Katherine D. Crew, Wendy K. Chung
Journal: Annals of Internal Medicine (2019)

Personalization of care through precision medicine and, more specifically, genetic testing is altering the treatment of breast cancer. Genetic testing is used in germline and tumor testing, with each providing distinct data to guide management. Germline testing supports more accurate risk evaluation to inform screening and risk-reducing medical and surgical strategies. Tumor testing can inform cancer recurrence risk assessment and cancer treatment options. This article reviews how genetic testing informs treatment and potential risks for a patient with breast cancer and her family. Hereditary cancer genetic testing of family members should include a discussion of potential results, adverse effects, clinical management options, and insurance coverage and address concerns about privacy or discrimination. Genetic professionals are available to assist with educating, testing, and treating patients with increased cancer risk.
P2.14-55 Real-World Safety and Efficacy Data of Osimertinib in Patients from Japan with EGFR T790M-Positive NSCLC
Authors: Y. Ohe, T. Kato, W. Shimizu, K. Sakamoto, M. Sugeno, R. Tamura, T. Tokimoto, A. Gemma
Journal: Journal of Thoracic Oncology (2019)
Comparative Studies on a Branded Recombinant Factor VIIa and Its Generic Version to Demonstrate Bioequivalence
Authors: Nasir Sadeghi, Zafar Siddiqui, Omer Iqbal, Schuharazad Abro, Debra Hoppensteadt, Michael Mosier, Jeanine Walenga, Jawed Fareed, Ahmed Kouta
Journal: Blood (2017)
P1.01-130 Clinical Experience with Nintedanib in Previously Treated Non-Small Cell Lung Cancer in Spain: A Retrospective Multicenter Study
Authors: P. Cruz, L. Gutiérrez Sainz, C. Aguado, M. Antoñanzas, X. Mielgo, L. Cabezón, L.E. Chara, E. Martinez Moreno, Y. Lage Alfranca, A. Velastegui, M. Sotelo, A. Garcia Rueda, M.E. Olmedo, S. Martínez Recio, J. De Castro Carpeno
Journal: Journal of Thoracic Oncology (2019)